Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
Multiple Myeloma
Teclistamab Showed Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Read More
Multiple Myeloma
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
Read More
Multiple Myeloma
Evaluating Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
Read More
Multiple Myeloma
Iberdomide, a Cereblon E3 Ligase Modulator, plus Dexamethasone Demonstrated Activity in Heavily Pretreated Patients with Multiple Myeloma
Read More
Multiple Myeloma
Once-Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: The SKylaRk Trial
Read More
Multiple Myeloma
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
Read More
Multiple Myeloma
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
Read More
Multiple Myeloma
ALLO-715, an Allogeneic Anti-BCMA CAR T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: Results from UNIVERSAL
Read More
Multiple Myeloma
2022 Year in Review: Multiple Myeloma Introduction
Read More
Multiple Myeloma
First-in-Human Phase 1/2 Study of REGN5458 in Heavily Pretreated Patients with Multiple Myeloma
Read More
1
2
3
4
Page 1 of 10
Results 1 - 10 of 98